Researchers found 44 cancer-targeting T cell receptors in routine clinical genomics data from 150,000 tumours. Read how this ...

Anaheim Bio launches with an oversubscribed €40M Series A to advance ANA-1, a CPPD inhibitor, toward the clinic. Learn how ...

Novo Nordisk is terminating its cardiometabolic RNA-editing deal with Korro Bio, effective February 2027. Read what it means for Korro's programs and rights.

AusperBio reports AHB-137 sustained functional cure in 16 of 17 evaluable NA-treated hepatitis B patients at 12 months off ...

Brii Bio's Phase IIb ENRICH data show BRII-179 priming drove 42% HBsAg loss in hepatitis B. Read the full results and what they mean for a functional cure.

Alfasigma's Jyseleca (filgotinib) is now EU-approved for adults with active axial spondyloarthritis. Read what it means for ...

Johnson & Johnson's Rybrevant Faspro earns FDA accelerated approval for recurrent or metastatic HNSCC. Learn who qualifies ...

Alamar Biosciences (Nasdaq: ALMR) and Finland-based Nightingale Health have launched UKB-PRISM, a study of 80,000 UK Biobank ...

Roche is using Chai Discovery's AI models across multiple drug discovery programs. Read the full story on this latest 2026 ...

A2 Biotherapeutics' MSLN-targeting A2B694 CAR T therapy produced a 12-month-plus complete response in one NSCLC patient. Read ...

Cambridge spinout T-Therapeutics closes $133m Series B to advance TCR bispecifics in cancer and autoimmune disease. Read the full story for what's next.

Moderna's mRNA-2808 yields four confirmed responses in Phase I/II myeloma study targeting BCMA, GPRC5D and FcRH5. Read the ...